DrugPatentWatch Database Updates: New Patent Additions
✉ Email this page to a colleague
DrugPatentWatch Database Updates: New Patent Additions
Applicant | Tradename | Generic Name | Dosage | NDA | Number | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Requested | Patent Expiration | Date Submitted | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tolmar | ELIGARD KIT | leuprolide acetate | POWDER | 021379 | 001 | Jul 24, 2002 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | 2024-04-15 | ||||
Gilead Sciences Inc | VEMLIDY | tenofovir alafenamide fumarate | TABLET | 208464 | 001 | Nov 10, 2016 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | 2016-11-28 | U-1275 | TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER | |
Gilead Sciences Inc | VEMLIDY | tenofovir alafenamide fumarate | TABLET | 208464 | 001 | Nov 10, 2016 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | 2016-11-28 | U-3880 | TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION IN ADULTS AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 25 KG | |
Gilead Sciences Inc | VEMLIDY | tenofovir alafenamide fumarate | TABLET | 208464 | 001 | Nov 10, 2016 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | 2016-11-28 | U-999 | TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS | |
Gilead Sciences Inc | VEMLIDY | tenofovir alafenamide fumarate | TABLET | 208464 | 001 | Nov 10, 2016 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||||
Gilead Sciences Inc | VEMLIDY | tenofovir alafenamide fumarate | TABLET | 208464 | 001 | Nov 10, 2016 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | 2016-11-28 | U-1275 | TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Number | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Requested | >Patent Expiration | >Date Submitted | >Usecode | >Patented / Exclusive Use |